Clinical trial Recruiting at 1 site Observational Ages 20 to 90 Women only

Using ultrasound to evaluate breast cancer biomarkers

Official title: VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients

Run by UNC Lineberger Comprehensive Cancer Center · NCT06878547 · Data updated 2026-11-12

This study is testing whether special ultrasound techniques can help doctors understand how breast tumors behave and respond to chemotherapy in women with either benign or malignant tumors.

Quick facts

Study typeObservational
Ages20 Years to 90 Years
SexWomen only
Enrollment250 (estimated)
SponsorUNC Lineberger Comprehensive Cancer Center
Academic / other
Drugs / interventionschemotherapy, Radiation
Locations1 site (Chapel Hill, North Carolina)
StatusRecruiting
StartedMarch 7, 2025
Main results expectedAugust 25, 2027
Study endsFebruary 24, 2028
Registry record updatedJune 2, 2026
Trial IDNCT06878547 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 20-90 with sonographically visible breast lesions rated BI-RADS 4a, 4b, 4c, or 5, or those with BI-RADS 6 lesions undergoing neoadjuvant chemotherapy.

Probably not a fit

Patients who may not benefit include those with breast implants, a history of mastectomy, or those unable to provide informed consent.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the correlation between non-invasive ultrasound measurements of tissue stiffness, viscosity, and anisotropy with breast tumor malignancy and response to chemotherapy. It involves two arms: one with women having benign or malignant breast tumors and another with women undergoing neoadjuvant chemotherapy. The research utilizes advanced ultrasound technologies, including Acoustic Radiation Force Impulse (ARFI) and Viscoelastic Response (VisR) ultrasound, to gather data on breast tissue characteristics. The goal is to determine how these ultrasound-derived metrics can aid in cancer diagnosis and staging.

Why it matters

Potential benefit: If successful, this study could provide a non-invasive method for better diagnosing and staging breast cancer, potentially improving treatment outcomes.

How similar studies have gone: Other studies have shown promise in using ultrasound technologies for breast cancer diagnostics, but this specific approach is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria (Arm 1):

* Subjects are 20-90 years of age
* Subjects are female
* Breast lesion is sonographically visible with B-Mode ultrasound on diagnostic workup
* Breast lesion(s) have BI-RADS 4a, 4b, 4c, or 5 rating

Exclusion Criteria (Arm 1):

* Inability to provide informed consent
* Inability to communicate in English
* Inability to remain motionless for 15 minutes
* Subjects with breast implants
* Breast mass is deeper than 4 cm from skin surface
* Subjects who are pregnant or lactating
* Subjects who have pacemakers or implanted cardioverters
* Subjects with a history of mastectomy
* Previous biopsy or surgery to the site of the mass, surgical excision of mass of interest
* Subject is male

Inclusion Criteria (Arm 2):

* Subjects are 20-90 years of age
* Subjects are female
* Breast lesion is sonographically visible with B-Mode ultrasound on diagnostic workup
* Breast lesion(s) have BI-RADS 6 rating, subject will be undergoing NAT for stage 2 or 3 malignant breast lesion(s)

Exclusion Criteria (Arm 2):

* Inability to provide informed consent
* Inability to communicate in English
* Inability to remain motionless for 15 minutes
* Subjects with breast implants
* Breast mass is deeper than 4 cm from skin surface
* Subjects who are pregnant or lactating
* Subjects who have pacemakers or implanted cardioverters
* Subjects with a history of mastectomy
* Previous biopsy or surgery to the site of the mass, surgical excision of mass of interest
* Subject is male

Where it's running

  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina, United States
    Recruiting

Study contacts

  • Principal investigator: Caterina Gallippi, PhD — Lampe Joint Department of Biomedical Engineering
  • Study coordinator: Desma Jones
  • Email: desma_jones@med.unc.edu
  • Phone: 919-843-9463

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.